Takeda Pharmaceutica
4502
End-of-day quote Tokyo - 09/20
4713JPY
+0.58%
Income Statement Evolution
Annual Income Statement Data
Actuals in M JPY Estimates in M JPY
Fiscal Period March 20182019
Sales1 770 5311 761 571
EBITDA437 460393 879
Operating profit (EBIT)--
Pre-Tax Profit (EBT)217 205211 443
Net income186 886153 159
EPS ( JPY )239209
Dividend per Share ( JPY )180180
Yield3,47%3,84%
Announcement Date05/14/2018
06:00am
-
Finances - Leverage
Actuals in M JPY Estimates in M JPY
Fiscal Period March 20182019
Debt610 494679 746
Finance--
Operating income (EBITDA)437 460393 879
Leverage
(Debt/EBITDA)
1,40x1,73x
Capital Expenditure67 00588 151
Book Value Per Share (BVPS)2 557  JPY2 582  JPY
Cash Flow per Share490  JPY424  JPY
Announcement Date05/14/2018
06:00am
-
Balance Sheet Analysis
Financial Ratios
Size 2019e 2020e
Capitalization 3 723 961 M JPY -
Entreprise Value (EV) 4 403 707 M JPY 4 264 729 M JPY
Valuation 2019e 2020e
P/E ratio (Price / EPS) 22,4x 18,7x
Capitalization / Revenue 2,11x 2,05x
EV / Revenue 2,50x 2,35x
EV / EBITDA 11,2x 9,88x
Yield (DPS / Price) 3,84% 3,84%
Price to book (Price / BVPS) 1,81x 1,76x
Profitability 2019e 2020e
Operating Margin (EBIT / Sales) - -
operating Leverage (Delta EBIT / Delta Sales) - -
Net Margin (Net Profit / Revenue) 8,69% 11,2%
ROA (Net Profit / Asset) 4,60% 5,14%
ROE (Net Profit / Equities) 7,37% 9,26%
Rate of Dividend 86,0% 71,7%
Balance Sheet Analysis 2019e 2020e
CAPEX / CA   5,00% 4,37%
Cash Flow / Sales 18,9% 21,4%
Capital Intensity (Assets / Sales) 1,89x 2,19x
Financial Leverage (Net Debt / EBITDA) 1,73x 1,25x
Price Earning Ratio
BNA & Dividende